This technology includes polyclonal antibodies against MLL3 (KMT2C), MLL4, PA1, UTX And PTIP for the development of treatments for development diseases and cancer. Enhancers play a central role in cell-type-specific gene expression and are marked by H3K4me1/2. Active enhancers are further marked by H3K27ac. However, the methyltransferases responsible for H3K4me1/2 on enhancers remain elusive. Furthermore, how these enzymes function on enhancers to regulate cell-type-specific gene expression is unclear. Our findings suggest that loss-of-function mutations in MLL3 and MLL4 would impair H3K4me1/2 on enhancers, which lead to defects in enhancer activation, cell-type-specific gene expression and cell differentiation. Such a mechanism may contribute to the pathogenesis of these developmental diseases and cancers.
Treatment of various developmental diseases and cancers.
Using MLL3/4 KO human and mouse cells, we demonstrated that MLL3/4 are major mammalian H3K4me1/2 methyltransferases in vivo and partially redundant each other.